Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection
about
Lipid nanoparticles for targeted siRNA delivery - going from bench to bedsideDNA Nanotechnology for Cancer TherapyPrevention and Treatment of Recurrent Hepatitis B after Liver TransplantationTherapeutic Oligonucleotides Targeting Liver Disease: TTR AmyloidosisTherapeutic Strategies and New Intervention Points in Chronic Hepatitis Delta Virus InfectionProgress and Prospects of Anti-HBV Gene Therapy DevelopmentHepatitis delta: epidemiology, diagnosis and management 36 years after discoveryLipid nanoparticles as carriers for RNAi against viral infections: current status and future perspectivesManagement of chronic hepatitis B infection: current treatment guidelines, challenges, and new developmentsHepatitis B: future curative strategiesInhibitor-Based Therapeutics for Treatment of Viral HepatitisKnocking down disease: a progress report on siRNA therapeuticsCurrent and future antiviral drug therapies of hepatitis B chronic infectionAsian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Phosphorylation-specific status of RNAi triggers in pharmacokinetic and biodistribution analysesMechanisms of nanoparticle-mediated siRNA transfection by melittin-derived peptides.Enhanced antiviral and antifibrotic effects of short hairpin RNAs targeting HBV and TGF-β in HBV-persistent mice.RNAi therapies: drugging the undruggable.Recent In Vivo Evidences of Particle-Based Delivery of Small-Interfering RNA (siRNA) into Solid TumorsProspects for inhibiting the post-transcriptional regulation of gene expression in hepatitis B virus.Hepatitis B virus: new therapeutic perspectives.Bioenergetics and gene silencing approaches for unraveling nucleotide recognition by the human EIF2C2/Ago2 PAZ domain.Antiviral therapies and prospects for a cure of chronic hepatitis B.Unveiling the roles of HBV polymerase for new antiviral strategiesA role for peptides in overcoming endosomal entrapment in siRNA delivery - A focus on melittinSystemic Administration of siRNA via cRGD-containing Peptide.Combinatorial RNA Interference Therapy Prevents Selection of Pre-existing HBV Variants in Human Liver Chimeric Mice.Scalable preparation of poly(ethylene glycol)-grafted siRNA-loaded lipid nanoparticles using a commercially available fluidic device and tangential flow filtration.Short-interference RNAs: becoming medicines.Journey to the Center of the Cell: Current Nanocarrier Design Strategies Targeting Biopharmaceuticals to the Cytoplasm and NucleusReductively Responsive Hydrogel Nanoparticles with Uniform Size, Shape, and Tunable Composition for Systemic siRNA Delivery in Vivo.Towards the elimination and eradication of hepatitis B.Pharmacokinetic Behaviors of Intravenously Administered siRNA in Glandular Tissues.An Effective Molecular Target Site in Hepatitis B Virus S Gene for Cas9 Cleavage and Mutational InactivationThe delivery of therapeutic oligonucleotidesA Tat-conjugated Peptide Nucleic Acid Tat-PNA-DR Inhibits Hepatitis B Virus Replication In Vitro and In Vivo by Targeting LTR Direct Repeats of HBV RNA.A pliable electroporation patch (ep-Patch) for efficient delivery of nucleic acid molecules into animal tissues with irregular surface shapes.An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases.In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma.Phase I clinical trial of SYL040012, a small interfering RNA targeting β-adrenergic receptor 2, for lowering intraocular pressure.
P2860
Q26741449-75DBBAA4-E34B-49F0-B643-E72079F432A5Q26750363-561CEC52-372C-41C1-B162-AF9ECFD393FFQ26751777-4576AA88-3F6F-4994-8F88-07493345C47DQ26782089-8DE3E2F8-9ECF-4AFB-A850-09D55674760BQ26795919-55AA309B-014E-45DF-87AB-B540E2586C67Q26799228-5625DA3E-3BB1-4984-A98E-40900DEAFC9EQ26849602-5525D3FA-CC2B-4507-9C85-07621CBC8052Q26859021-2FC0EC8D-D29B-4548-88E0-DBA18C84C9E3Q27008984-B691FB78-19C6-4853-A825-E5A6D3593517Q27011623-3135F9D3-7BFA-4F84-8596-051823DDACF8Q28073697-6A129A46-65BB-4611-B5E2-F7E5FFE1A551Q28082939-A5173800-DB0E-47D0-89F7-5E65F7FEF80AQ28084820-A498A601-862A-47BF-811B-3EB29EEE290EQ30391932-5A2286FC-A3DF-428A-9ED6-44056CB9F1BFQ33554206-B49062FB-984C-4282-A91B-751DF7C88023Q33581506-4893A917-03C9-4BD0-B88C-595E19A6750DQ33819100-F1A079D3-CACA-4C89-AE73-15144FCD0E64Q34131220-279FEBFD-C9B4-49C5-9B53-0E4BCC935363Q34165321-55A4D38D-92AB-429B-9312-DBC032CBDE73Q34428554-CB2A9A6E-13C0-48AB-9BF5-A0F8168683AEQ34507250-82A86800-09CF-4568-8D0B-7BAFEFA1D4E7Q35161618-164082F9-79F1-4919-9E1F-EA8F0C75F32EQ35245231-EB4113B3-ECDE-4594-96A5-08050A25B5E0Q35441503-7ED580A0-0356-4761-A18C-36A7C7E34603Q35967737-BE6C7B6B-B495-48DB-87F1-001519E526DAQ35989535-AF4B7AED-331A-4864-BD38-7692A28FC0A4Q36181757-AF4C4CFC-A350-40AF-AF17-9A947EEA539FQ36269077-10F994E2-7BF6-4A5A-91F2-E87B12414605Q36347546-7FD391A6-EDCB-4135-B654-34DE749C63C2Q36689670-68CAECEB-6FA9-4ED2-A76F-E9BADA1FD262Q36821612-8FD6D892-13B5-4B84-9093-5D57BE37CCD3Q37098214-CA6D88FE-ADC1-4479-966D-8DC8000A7CE8Q37112951-67C339E1-4BDB-4E90-8CBB-159AAE21B5AFQ37201993-B3A3FE72-D910-4D61-B050-68AF35D08494Q37210936-8C11D99D-4A18-41A2-BB57-18E4AC65599CQ37238749-CF4E8EB3-7947-466E-85DB-AF402A783722Q37499778-AFA56BE5-00FC-4CDC-97C5-FA003EC8A95BQ37562042-A377B06E-01DE-404C-ADAA-B51139412AD6Q37690470-6DA4D959-FE46-4F77-801B-3559FC5EC2ADQ37690494-E3050DA8-9B26-46CB-9F4E-4CC23546024F
P2860
Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Hepatocyte-targeted RNAi thera ...... ic hepatitis B virus infection
@en
type
label
Hepatocyte-targeted RNAi thera ...... ic hepatitis B virus infection
@en
prefLabel
Hepatocyte-targeted RNAi thera ...... ic hepatitis B virus infection
@en
P2093
P2860
P356
P1433
P1476
Hepatocyte-targeted RNAi thera ...... ic hepatitis B virus infection
@en
P2093
Alan McLachlan
Christine I Wooddell
Claudia E Oropeza
Darren H Wakefield
David B Rozema
David L Lewis
Holly L Hamilton
Ingo Roehl
Jason J Klein
Jochen Deckert
P2860
P304
P356
10.1038/MT.2013.31
P577
2013-02-26T00:00:00Z